(Q38252936)

1 September 2017

1 reference

title

Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate (English)

1 reference

1 September 2017

R A Chez

1

1 reference

1 September 2017

language of work or name

English

0 references

publication date

1 May 1989

1 reference

American Journal of Obstetrics and Gynecology

1 September 2017

published in

1 reference

1 September 2017

volume

160

1 reference

1 September 2017

issue

5 Pt 2

1 reference

1 September 2017

page(s)

1296-1300

1 reference

New progestogens in oral contraceptives

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980016-X

Biotransformation of norgestimate in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980016-X

The affinity of norgestimate for uterine progestogen receptors and its direct action on the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980016-X

Gestoden, an innovative progestogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980016-X

Effects of norgestimate (0.250 mg) in combination with ethinyl estradiol (0.035 mg) on cervical mucus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980016-X

Two oral contraceptives, efficacy, serum proteins, and lipid metabolism. A comparative multicentre study on a triphasic and a fixed dose combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980016-X

Effects of 180 micrograms and 250 micrograms norgestimate on pituitary-ovarian function and cervical mucus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980016-X

Optimum dosage of an oral contraceptive. A report from the study of seven combinations of norgestimate and ethinyl estradiol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980016-X

Changes in serum apo-lipoprotein AI and sex-hormone-binding globul in levels after treatment with two different progestins administered alone and in combination with ethinyl estradiol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980016-X

Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980016-X

Fibrinopeptide A plasma levels during low-estrogen oral contraceptive treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980016-X

Coagulation effects of oral contraception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980016-X

Metabolic effects of oral contraceptives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980016-X

Triphasic oral contraception: metabolic effects in normal women and those with previous gestational diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980016-X

A randomized crossover comparison of two low-dose contraceptives: effects on serum lipids and lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980016-X

Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980016-X

Effects of seven low dose combined oral contraceptives on high density lipoprotein subfractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9378%2889%2980016-X

10.1016/S0002-9378(89)80016-X

7 January 2021

Identifiers

DOI

1 reference

1 September 2017

1 reference